Last reviewed · How we verify

CST-3056 — Competitive Intelligence Brief

CST-3056 (CST-3056) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK9 inhibitor. Area: Oncology.

phase 2 CDK9 inhibitor CDK9 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CST-3056 (CST-3056) — CuraSen Therapeutics, Inc.. CST-3056 is a small molecule inhibitor of the CDK9 enzyme.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CST-3056 TARGET CST-3056 CuraSen Therapeutics, Inc. phase 2 CDK9 inhibitor CDK9
RO4917838 RO4917838 Hoffmann-La Roche phase 3 CDK9 inhibitor CDK9
TPX-114 TPX-114 Tego Science, Inc. phase 3 CDK inhibitor CDK9

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK9 inhibitor class)

  1. Eli Lilly and Company · 2 drugs in this class
  2. Astellas Pharma Inc · 1 drug in this class
  3. Bayer · 1 drug in this class
  4. CuraSen Therapeutics, Inc. · 1 drug in this class
  5. Eagle Pharmaceuticals, Inc. · 1 drug in this class
  6. Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CST-3056 — Competitive Intelligence Brief. https://druglandscape.com/ci/cst-3056. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: